Clinical trials: Dalteparin
Chemotherapeutic Agent Toxicity, Pancreatic Cancer
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Pancreatic Cancer, Thromboembolism
- Trial name
- PAM07 (NCT00662688)
- Testing
- daltéparine, Chemotherapy at the investigator's discretion
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Anticoagulants and Bleeding Disorders
Comparison of Heparin Anti-Xa Activity From Central Venous Catheter Samples Using a 5 mL Syringe Flush or a Vacuum Tube Flush Versus Peripheral Vein Samples in ICU Patients
The goal is to investigate whether blood samples drawn from a central venous catheter can provide reliable measurements of unfractionated heparin (UFH) anti-Xa activity, compared to the standard method of peripheral vein…
- Trial name
- CASSANDRA (NCT07183605)
- Testing
- catheter flushing techniques
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Sepsis
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of…
- Trial name
- NCT05634057
- Testing
- Anisodamine hydrobromide combined with heparin
- Where
- China
- Volunteers
- 782 people
- Sponsor
- Chen Ying
Neoplasms, Venous Thromboembolism
Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism
Low molecular weight heparins (LMWH) are the reference molecule for the long term treatment of venous thromboembolism (VTE) in cancer patients but remains, however, associated with a high risk of recurrent thromboembolism.
- Trial name
- aXa (NCT02898051)
- Where
- 8 sites in France
- Volunteers
- 370 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Diseases, Obesity
Epidemiologic Data of Patients in a Teaching Hospital
This small cross-sectional epidemiological study is designed to evaluate the prevalence of the following parameters in hospitalized patients in a tertiary teaching hospital (medical department only): kidney insufficiency obesity…
- Trial name
- NCT00114335
- Where
- Switzerland
- Volunteers
- 352 people
- Sponsor
- Luzerner Kantonsspital
Multiple Myeloma, Venous Thromboembolism
Thrombosis in Patients With Multiple Myeloma in an University Medical Center
Main research question: What is the present venous thrombosis incidence and what are the current practices of prescribing thromboprophylaxis in patients with multiple myeloma (MM)? Design: The present study is a retrospective…
- Conditions
- Multiple Myeloma, Venous Thromboembolism, Arterial Thromboembolism
- Trial name
- THRIMM (NCT05541978)
- Testing
- Multiple myeloma
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Catalina Codreanu
Renal Insufficiency, Chronic, Deep Venous Thrombosis, Protection Against
Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses
The purpose of this study is to assess if accumulation of anti-Xa activity occurs after repeated daily administration of prophylactic doses of tinzaparin in patients with severe chronic kidney disease (CKD) requiring…
- Trial name
- STRIP (NCT02719418)
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction
COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device
A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.
- Conditions
- Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction, Sarcopenia, Ultrasonography
- Trial name
- COOLEY (NCT06079021)
- Testing
- CytoSorb
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Antwerp
ARDS, COVID-19
Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure
A monocentric observational study evaluates the accuracy of anticoagulation monitoring in critically ill patients on ECLS (extracorporeal life support) using new markers of the effect of direct thrombin inhibitors and also the…
- Trial name
- NCT06038682
- Testing
- Argatroban Injection, Heparin
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Ostrava
Venous Thromboembolism
Low Molecular Weight hEparin vs. Aspirin Post-partum
This is single centre pilot, randomized controlled trial assessing postpartum prophylactic anticoagulation with 3 weeks of LMWH followed by 3 weeks of Aspirin compared to standard of care of prophylactic LMWH for 6 weeks at…
- Trial name
- LEAP (NCT05058924)
- Testing
- Prophylactic low molecular weight heparin, Low molecular weight heparin and low-dose aspirin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Mount Sinai Hospital, Canada
Oncologic Diseases, Coagulation Defect
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
- Conditions
- Oncologic Diseases, Coagulation Defect, Pain Management
- Trial name
- NCT07384013
- Testing
- metamizole
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rambam Health Care Campus
Chronic Kidney Failure
Reduction of Heparin Dose in Dialysis With Evodial System
The current clinical study aims at defining an index of Anti Xa, which is the marker to evaluate the activity of heparin, at the end of the dialysis treatment and so showing the possibility to decrease heparin doses during…
- Trial name
- RHODES (NCT00781690)
- Testing
- Evodial hemodialysers and Evodia blood lines
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 53 people
- Sponsor
- Vantive Health LLC
Thromboembolic Disease
HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) provide anticoagulation through their anti-Xa and anti-IIa activity.
- Trial name
- HIMA (NCT07302620)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Strasbourg, France
Recurrent Spontaneous Abortion
Prospective Study of BMD and Ca-P Metabolism in RSA Patients: LMWH Use Versus Control
The goal of this prospective observational study is to learn about the effect of low molecular weight heparin (LMWH) application on bone mineral density (BMD) and on calcium-phosphorus metabolism in patients with recurrent…
- Trial name
- NCT05878574
- Testing
- Low molecular weight heparin
- Where
- China
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Aimin Zhao
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO)
Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation
The aim of this observational pilot study is to evaluate the effectiveness and safety of low-molecular-weight heparin (LMWH) compared to unfractionated heparin (UFH) as anticoagulation in perioperative ECMO during bilateral lung…
- Conditions
- Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders
- Trial name
- LUX-ET-LT (NCT06868823)
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- University Hospital, Motol
Lung Neoplasms, Esophageal Neoplasms
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
The purpose of this study is to determine whether the use of different dose of LMWH compared with fondaparinux for thromboprophylaxis is efficacious and safety after thoracic surgery.
- Conditions
- Lung Neoplasms, Esophageal Neoplasms, Venous Thromboembolism
- Trial name
- NCT01267305
- Testing
- Fondaparinux, Nadroparin Calcium
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Shanghai Zhongshan Hospital
Venous Thromboembolism
Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
The aim of this study is to evaluate the efficacy and safety of individual dose adjustment of low molecular weight heparin (LMWH) based on the results of the thrombodynamics test (TD) in patients at extremely high risk of…
- Trial name
- IDAHeT (NCT04710732)
- Testing
- Standard Enoxaparin 40 mg once-daily before randomization, Standard Enoxaparin 40 mg once-daily after randomization, Escalated Enoxaparin 30 mg twice-daily after randomization
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Pirogov Russian National Research Medical University
Venous Thromboembolism, Deep Vein Thrombosis
Fixed Dose Heparin Study
FIDO was a multicentred randomized, open-label trial that compared fixed-dose UFH with fixed-dose LMWH for initial treatment of VTE. Patients were followed for 3 months during which they received warfarin (target INR 2.0-3.0).
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT00182403
- Testing
- UFH 250 U/kg or LMWH 100 U/kg sc twice daily
- Where
- 8 sites in Canada, New Zealand
- Volunteers
- 866 people
- Sponsor
- McMaster University
Aortic Diseases, Arterial Disease
Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)
Activated clotting time (ACT) is currently recommended to monitor high concentrations heparin anticoagulation. ACT-LR was specifically designed to measure the activity of low dose of heparin used during endovascular surgery.
- Conditions
- Aortic Diseases, Arterial Disease, Thrombosis
- Trial name
- AXAES (NCT05554055)
- Testing
- Anti Xa activity measurement.
- Where
- France
- Sponsor
- Hospices Civils de Lyon